What Astellas Pharma does

Astellas Pharma Inc. is a Tokyo-headquartered global pharmaceutical company (TYO:4503) founded in 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. The company develops and commercializes prescription medicines across five strategic therapeutic areas: oncology (Xtandi, PADCEV, Vyloy, Xospata), ophthalmology (Izervay), urology, immunology, and women's health (Veozah), with a workforce of more than 13,500 employees operating in over 70 countries.

Astellas operates across multiple therapeutic modalities including small molecules, biologics, antibody-drug conjugates, gene therapies, cell therapies, and targeted protein degradation. The company has assembled proprietary technology platforms through a series of acquisitions and partnerships: ACCEL convertibleCAR cell therapy (Xyphos Biosciences), Universal Donor Cell technology (Universal Cells, 2018), AI-engineered AAV capsids (Dyno Therapeutics), immunostimulatory ADCs (Sutro Biopharma, ASP2998), and the first-in-class KRAS G12D targeted protein degrader ASP3082. Pipeline assets include VIR-5500 (PSMA TCE for prostate cancer, partnered with Vir Biotechnology) and isaralgagene civaparvovec for Fabry disease (acquired from Sangamo). Manufacturing operations span Ireland (Dublin, Killorglin, and a new Tralee fill-finish facility opening 2027) and Japan (Tsukuba, Toyama, Yaizu, Takahagi).

Astellas generates revenue primarily through proprietary pharmaceutical product sales across oncology, ophthalmology, urology, immunology, and women's health, supplemented by licensing and royalty income (e.g., 50/50 U.S. profit split with Pfizer on PADCEV). FY2025 revenue reached ¥2,139.2 billion (~$14.2 billion) with 11.9% year-over-year growth, marking the first time the company surpassed ¥2 trillion. Revenue is heavily concentrated in Xtandi (¥960.8 billion, ~45% of total) ahead of its 2027 U.S. patent expiration, which the company is offsetting through the Sustainable Margin Transformation cost program (target ¥200 billion in savings) and growth from five strategic brands projected to cover 50% of revenue by FY2030. Distribution relies on direct field sales forces, medical science liaisons, co-promotion arrangements (notably Pfizer for PADCEV), and specialty pharmacy access programs in over 70 countries.

Name

Astellas Pharma

Legal name

Astellas Pharma Inc.

Website

https://astellas.com

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Astellas Pharma is a Tokyo-headquartered global pharmaceutical company (TYO:4503) developing and commercializing prescription medicines across oncology, ophthalmology, urology, immunology, and women's health, serving patients in more than 70 countries with 13,500+ employees.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Nephrology & Urology Pharmaceuticals (HLAIAAAM), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Prescription pharmaceuticals
• Oncology therapeutics
• Gene therapy development
• Cell therapy manufacturing
• Antibody-drug conjugates

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices24 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Astellas generates the vast majority of its revenue from the sale of proprietary pharmaceutical products across oncology, ophthalmology, urology, immunology, and women's health. Key brands include Xtandi (prostate cancer), PADCEV (bladder cancer), Izervay (geographic atrophy), Vyloy (gastric cancer), Veozah (vasomotor symptoms), and Xospata (AML). FY2025 revenue reached ¥2,139.2 billion (approximately $14.2 billion), surpassing ¥2 trillion for the first time, with 11.9% year-over-year growth.
2. Licensing and Royalty Income: Astellas receives licensing fees and royalties from partnerships including from co-commercialization arrangements (e.g., U.S. profit sharing with Pfizer on PADCEV, 50/50 split with Vir Biotechnology on VIR-5500 U.S. profits). The company also generates income from milestone payments and upfront fees in strategic partnerships.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Astellas Pharma develops, manufactures, and commercializes proprietary prescription pharmaceutical products across five strategic therapeutic areas: oncology (Xtandi for prostate cancer, PADCEV for bladder cancer, Xospata for AML, Vyloy for gastric cancer), ophthalmology (Izervay for geographic atrophy), urology, immunology, and women's health (Veozah for menopausal vasomotor symptoms). The company generates revenue primarily from sales of these six strategic brands, supplemented by licensing/royalty income from partnerships and a deep pipeline of gene therapies, cell therapies, targeted protein degraders, and bispecific T-cell engagers developed in-house and through partnerships with Pfizer, Vir Biotechnology, Dyno Therapeutics, and Sutro Biopharma.

Product overview

Astellas Pharma is a global life sciences company that develops and commercializes pharmaceutical products across five strategic therapeutic areas: oncology (Xtandi, PADCEV, Vyloy, Xospata), ophthalmology (Izervay), urology, immunology, and women's health (Veozah). The company's marketed portfolio includes six strategic brands projected to cover 50% of revenue by fiscal 2030. Beyond commercialized products, Astellas maintains a robust pipeline including targeted protein degraders (ASP3082), bispecific antibodies (ASP2138), gene therapies (isaralgagene civaparvovec), and cell therapies. The company employs over 13,500 employees globally and operates in more than 70 countries, with research focused on immuno-oncology, targeted protein degradation, gene therapy, and regenerative medicine including blindness and vision restoration.

Differentiator

Problem solved

Functional benefit

Brands

• Xtandi: Prostate cancer treatment drug
• Padcev
• Izervay
• Veozah
• Xospata
• Vyloy
• Veoza
• Sobre a Vida Program
• Alma Diagnostic Program
• Claudinova

Products and services

• Xtandi (enzalutamide) Oral androgen receptor inhibitor for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and related prostate cancer indications; co-developed and co-promoted with Pfizer.
• PADCEV (enfortumab vedotin) Antibody-drug conjugate (ADC) targeting Nectin-4 for urothelial (bladder) cancer; approved in combination with pembrolizumab (Keytruda) for first-line metastatic urothelial cancer and as perioperative treatment for muscle-invasive bladder cancer; co-promoted with Pfizer in the U.S. on a 50/50 profit-share basis.
• Izervay (avacincaptad pegol) Complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD); acquired through the Iveric Bio acquisition.
• Vyloy (zolbetuximab) First-in-class CLDN18.2-targeted monoclonal antibody for the treatment of CLDN18.2-positive gastric and gastroesophageal junction adenocarcinoma.
• Veozah (fezolinetant) Non-hormonal neurokinin 3 (NK3) receptor antagonist for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause.
• Xospata (gilteritinib) FLT3 tyrosine kinase inhibitor for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation; supported by the Alma Diagnostic Program for FLT3 mutation testing.
• isaralgagene civaparvovec (ST-920) AAV-based gene therapy for the treatment of Fabry disease, in pivotal clinical development with rolling FDA review.
• VIR-5500 PSMA-targeted T-cell engager for the treatment of metastatic castration-resistant prostate cancer; co-developed with Vir Biotechnology under a global collaboration and co-commercialization agreement.

Quantifiable outcome

• PADCEV+Keytruda perioperative: 47% reduction in risk of tumor recurrence, progression, or death; 35% reduction in risk of death vs. chemotherapy (EV-304 Phase 3)
• +3 more outcomes

Named customers4 records

Segments7 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered core, strategic and minor.

• Sangamo Therapeutics (Fabry Disease Program)coreStrategic or Co-development Partner · 23 June 2026As part of Sangamo's Chapter 11 bankruptcy proceedings, Astellas agreed to purchase Sangamo's Fabry disease gene therapy program isaralgagene civaparvovec (ST-920) for $25 million upfront (potentially $50 million with milestones). The therapy is in pivotal stage with rolling FDA review ongoing. Astellas had a prior 2024 license agreement with Sangamo covering this program, which is now being purchased outright through the bankruptcy process.
• Eli Lilly (Sangamo Technology Platforms)strategicStrategic or Co-development Partner · 23 June 2026As stalking horse bidders in Sangamo's Chapter 11 bankruptcy, Eli Lilly is acquiring Sangamo's capsid delivery platform, zinc finger platform, modular integrase (MINT) platform, and prion disease program (ST-506) for $50 million. Astellas is separately acquiring Sangamo's Fabry disease program ST-920. This represents separate but parallel transactions from the same bankruptcy process.
• Dyno TherapeuticsstrategicTechnology or Integration · 8 April 2026Astellas exercised its option to license an AI-engineered AAV capsid from Dyno Therapeutics designed for targeted gene delivery to skeletal muscle. The $15 million upfront deal is Dyno's first muscle-targeting capsid license and validates its AI-powered capsid design platform for biological sequence design. Astellas assumes responsibility for subsequent preclinical, clinical, and commercialization activities.
• Sutro BiopharmastrategicTechnology or Integration · 1 April 2026Astellas partnered with Sutro Biopharma for the development of immunostimulatory antibody-drug conjugates (iADCs), including ASP2998 (TROP2-targeted iADC), using Sutro's site-specific conjugation platform. Sutro triggered $17.5 million in combined milestone payments for Astellas' programs. Initial Phase 1 results for STRO-004 expected mid-2026; Sutro presented preclinical data at AACR 2026.
• Vir BiotechnologycoreStrategic or Co-development Partner · 6 February 2026Astellas entered a global collaboration and co-commercialization agreement with Vir Biotechnology for VIR-5500, a PSMA-targeted T-cell engager for metastatic prostate cancer. Terms include $240 million upfront payment, $75 million equity investment at $10.36/share, up to $1.37 billion in milestones, and tiered double-digit royalties on ex-U.S. sales. U.S. profits and losses are split 50/50, with Astellas leading U.S. commercialization and retaining ex-U.S. rights. The deal closed in April 2026 following HSR Act clearance.
• Yaskawa Electric Corporation (Cellafa Bioscience)strategicTechnology or Integration · 6 March 2025Astellas established a joint venture with Yaskawa Electric called Cellafa Bioscience to digitize and automate cell therapy manufacturing using robotics and AI, including the dual-arm robot 'Maholo'. The partnership aims to address reproducibility, cost, and scalability challenges in cell therapy manufacturing. The JV is part of Astellas' strategy to use ophthalmology as a proving ground for broader regenerative medicine applications.
• EvopointminorStrategic or Co-development Partner · 19 December 2024Astellas entered an exclusive license agreement with Evopoint for the clinical development of CLDN18.2-targeted ADC ASP546C/XNW27011. This partnership provides access to a first-in-class ADC asset for gastric cancer and other CLDN18.2-positive solid tumors.
• AviadoBiominorStrategic or Co-development Partner · 8 October 2024Astellas entered a collaboration with AviadoBio for an AAV-based gene therapy program (AVB-101) for frontotemporal dementia, currently in Phase I/II clinical trials. The partnership strengthens Astellas' gene therapy capabilities in neurodegenerative diseases.
• Poseida Therapeutics (Xyphos Biosciences)coreStrategic or Co-development Partner · 1 May 2024Astellas' wholly-owned subsidiary Xyphos Biosciences entered a research collaboration and license agreement with Poseida Therapeutics to develop convertibleCAR programs targeting solid-tumor cancers, combining Poseida's allogeneic CAR-T platform with Xyphos' ACCEL technology. Terms: $50 million upfront, up to $550 million in development and sales milestones and contingency payments, plus low double-digit tiered royalties. Astellas also invested $50 million total ($25M equity + $25M for exclusive negotiation rights on P-MUC1C-ALLO1), gaining a board observer seat.

Scale indicators18 records

Recent moves11 records

Expansion highlights7 records

Broad incumbents

• Pfizer: Co-develops and co-promotes Xtandi and PADCEV with Astellas; a global pharmaceutical incumbent with overlapping oncology, women's health, and rare disease franchises, and a directly shared economic interest in Astellas' two largest assets.
• Merck & Co. Provides Keytruda as the combination partner for PADCEV across multiple indications; a major oncology incumbent whose pricing and lifecycle decisions directly shape PADCEV's commercial trajectory.
• Roche: Global oncology and ophthalmology leader with overlapping bladder cancer, AMD, and gene therapy programs; a comparable scale multinational with biologics manufacturing depth similar to Astellas.
• Novartis: Comparable in oncology (radioligand therapies, targeted protein degraders) and ophthalmology (Beovu for AMD); competes with Astellas in geographic atrophy indirectly and in oncology ADCs/targeted therapies broadly.
• AbbVie: Major oncology and women's health player with comparable immunology and women's health pipeline exposure; relevant peer for evaluating cross-therapeutic-area pharmaceutical R&D productivity.

Direct peers

• Takeda Pharmaceutical: Japan's other global pharmaceutical major with comparable oncology, rare disease, GI, and women's health exposure; closest domestic peer in scale, geographic mix, and therapeutic-area focus.
• Daiichi Sankyo: Japanese pharma peer competing directly in oncology ADCs (AstraZeneca-partnered Enhertu/Datroway) against Astellas' PADCEV and Sutro-platform iADCs, with similar R&D intensity and global commercialization ambitions.
• Bayer Pharmaceuticals: Directly competes with Veozah in women's health menopause vasomotor symptoms via Lynkuet, and competes with Astellas in oncology and women's health, making it a relevant therapeutic-area peer.
• Apellis Pharmaceuticals: Direct competitor in geographic atrophy with Syfovre, the primary rival to Astellas' Izervay acquired through Iveric Bio; a focused ophthalmology peer whose commercial performance is a direct read on Astellas' GA franchise.

Emerging players

• Vertex Pharmaceuticals: Highly relevant rare-disease gene therapy and targeted protein degrader peer; competes with Astellas in gene therapy modalities and shares the strategic focus on small patient populations with high per-patient economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@AstellasPharmaGlobal
• LinkedInlinkedin.com/company/astellaspharmainc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A15 records

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Astellas Pharma